November 12–15, Copenhagen, Denmark

Driving integrated access strategies through next generation evidence

Meet senior experts from Avalere Health at booth C3-065 to find out how our best-in-class, end‑to‑end policy, access, value, and evidence services are supporting leading life sciences companies, health plans, providers, and investors.

Connect with an Expert

Priority Topics

Avalere continues to be a strategic thought partner for navigating the intersections between policy, health economics, and market access. We can ensure your evidence generation efforts demonstrate high clinical value and applicability across borders. Our experts are available to discuss the following priorities at ISPOR Europe:

–Evidence Utility Across Markets: Policies such as the Joint Clinical Assessments (JCA) and the Inflation Reduction Act (IRA) are reshaping the value landscape globally. These changes highlight the importance of transferability, including aspects like cost effectiveness and the limitations of available data, and the need for “integrated” evidence plans that promote cross-border transferability.

-Value of Quantitative and Qualitative Data: Mixed-method research strategies are often best suited to address questions around health equity, SDOH, and the total disease impact. This includes not only the economic burden but also the indirect burden, encompassing indirect medical costs and the uncovered expenses shouldered by caregivers.

–Patient Centricity in HEOR: Increasingly, stakeholders are demanding non-traditional evidence to answer complex questions about patient outcomes in real-world treatment settings. It is critical to explore new ways to measure healthcare quality and develop shared decision-making tools to ensure that patients remain at the center of healthcare decisions.

-Early Pipeline Strategy: Early decision making is crucial given the substantial investment to conduct clinical trials and bring products to market. Our experts are adept at offering insights into investment decisions, the assessment of product lifecycles, clinical development programs, and the strategic planning of early pipeline development.